Every material Form 8-K Sensus Healthcare, Inc. has filed with the SEC since May 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Sensus Healthcare reported second-quarter 2026 revenue of $2.3 million, down $5.0 million from the prior-year quarter, and a net loss of $8.7 million, or $0.53 per share. The company said a sale of eight units was not recorded in Q2 because of financing approval timing and will be recognized in Q3, while a $5.7 million tax expense that includes a valuation allowance against deferred tax assets added to the loss.
Q2 2026 revenue was $2.3 million versus $7.3 million in Q2 2025, with 11 units sold compared with 19 a year earlier.
Net loss was $8.7 million, or $0.53 per share, compared with a net loss of $1.0 million, or $0.06 per share, in Q2 2025.
Adjusted EBITDA, a non-GAAP measure, was negative $3.0 million versus negative $1.8 million a year earlier.
Cash, restricted cash and cash equivalents fell to $15.2 million at June 30, 2026, from $18.3 million at March 31, 2026.
Sensus Healthcare entered a Loan Agreement dated June 2, 2026, with City National Bank of Florida for a revolving credit facility of up to $15,000,000, secured by all company assets and $2,230,000 in cash collateral. The filing states the facility replaces a prior facility from Fifth Third Bank, which has been terminated, and lists lender consent requirements for asset sales, new debt, liens and removal of key officers.
Maximum borrowings of $15,000,000; advances bear SOFR plus 3% per annum and mature June 5, 2027 unless extended by mutual agreement
Loan secured by $2,230,000 in cash collateral and a security interest in all company assets
Lender consent required for non-ordinary-course asset sales, additional debt, new liens, or removal of the CEO, President or CFO
Financial covenant requires a minimum debt service coverage ratio of 1.50
Sensus Healthcare reported first-quarter 2026 revenue of $3.4 million, down from $8.3 million a year earlier, as it shipped 14 systems versus 30 and had no direct sales to its historically largest customer. Net loss was $2.6 million, or $0.16 per share, matching the prior-year quarter only because of a $1.6 million income tax benefit, while Adjusted EBITDA worsened to negative $4.2 million.
Revenue was $3.4 million versus $8.3 million for Q1 2025; the company shipped 14 SRT systems versus 30 in the prior-year period.
Net loss was $2.6 million, or $0.16 per share, the same per-share loss as Q1 2025, and included a $1.6 million income tax benefit.
Adjusted EBITDA was negative $4.2 million, compared with negative $2.5 million in Q1 2025.
Cash and cash equivalents were $18.3 million at March 31, 2026, down from $22.1 million at December 31, 2025, with no debt.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Sensus Healthcare, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →